[{"address1": "116 Huntington Avenue", "address2": "Suite 703", "city": "Boston", "state": "MA", "zip": "02116", "country": "United States", "phone": "617-468-4219", "website": "https://www.bicara.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Ms. Claire  Mazumdar Clemon M.B.A., Ph.D.", "age": 34, "title": "CEO & Director", "yearBorn": 1989, "fiscalYear": 2023, "totalPay": 650000, "exercisedValue": 0, "unexercisedValue": 578357}, {"maxAge": 1, "name": "Mr. Ryan  Cohlhepp Pharm.D.", "age": 47, "title": "President, COO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 660000, "exercisedValue": 0, "unexercisedValue": 103783}, {"maxAge": 1, "name": "Mr. Ivan  Hyep M.B.A.", "age": 39, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 597500, "exercisedValue": 0, "unexercisedValue": 77109}, {"maxAge": 1, "name": "Ms. Lara S. Meisner J.D.", "age": 51, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Rachel  Salazar", "title": "SVP of R&D Strategy and Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sathish  Hasige Ph.D.", "title": "Senior VP and Head of Technical Operations & Supply Chain", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David  Raben M.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Angela  Windt", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeltje  Schulten M.B.A., M.D.", "title": "Senior Vice President of Clinical & Medical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jean-Paul  Rodrique", "title": "Senior Vice President of Quality", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 20.0, "open": 19.95, "dayLow": 19.75, "dayHigh": 20.52, "regularMarketPreviousClose": 20.0, "regularMarketOpen": 19.95, "regularMarketDayLow": 19.75, "regularMarketDayHigh": 20.52, "forwardPE": -12.546584, "volume": 226187, "regularMarketVolume": 226187, "averageVolume": 623847, "averageVolume10days": 445420, "averageDailyVolume10Day": 445420, "bid": 19.82, "ask": 20.55, "bidSize": 100, "askSize": 100, "marketCap": 1098595200, "fiftyTwoWeekLow": 18.33, "fiftyTwoWeekHigh": 27.94, "fiftyDayAverage": 23.838696, "twoHundredDayAverage": 23.838696, "currency": "USD", "enterpriseValue": 184563808, "floatShares": 592981, "sharesOutstanding": 54385900, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.0121, "heldPercentInsiders": 0.06959, "heldPercentInstitutions": 0.31689, "impliedSharesOutstanding": 54385900, "bookValue": -170.752, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -64842000, "trailingEps": -3.75, "forwardEps": -1.61, "enterpriseToEbitda": -3.166, "52WeekChange": -0.14566427, "SandP52WeekChange": 0.3593408, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "BCAX", "underlyingSymbol": "BCAX", "shortName": "Bicara Therapeutics Inc.", "longName": "Bicara Therapeutics Inc.", "firstTradeDateEpochUtc": 1726234200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "89c17e6e-41f3-3d01-85f9-cd0e48aa9b6d", "messageBoardId": "finmb_674698236", "gmtOffSetMilliseconds": -14400000, "currentPrice": 20.2, "targetHighPrice": 47.0, "targetLowPrice": 35.0, "targetMeanPrice": 41.0, "targetMedianPrice": 41.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 203855008, "totalCashPerShare": 199.162, "ebitda": -58299000, "totalDebt": 517000, "quickRatio": 12.689, "currentRatio": 12.827, "debtToEquity": 0.269, "operatingCashflow": -46063000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-17"}]